| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT07489495 A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell… |
Trial sites expanded: 25 -> 34 locations |
| 2026-06-09 | NCT07489495 A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell… |
Trial sites expanded: 20 -> 25 locations |
| 2026-06-09 | NCT04924075 Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL)… |
Enrollment increased: 322 -> 355 participants |
| 2026-06-09 | NCT04924075 Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL)… |
date change Primary completion pushed: 2029-06-04 -> 2029-12-27 |
| 2026-06-09 | NCT04924075 Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL)… |
date change Completion pushed: 2029-06-04 -> 2029-12-27 |
| 2026-06-09 | NCT07405164 Extension Study for Participants in Studies That Include Belzutifan… |
Trial sites expanded: 15 -> 20 locations |
| 2026-05-30 | NCT07489495 A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell… |
Trial sites expanded: 13 -> 20 locations |
| 2026-05-27 | NCT07489495 A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell… |
Trial sites expanded: 8 -> 13 locations |
| 2026-05-19 | NCT06428396 Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer… |
date change Completion pushed: 2028-10-07 -> 2028-12-25 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-05-18 | NCT07593040 Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07227402 | A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer… | Renal Cell Carcinoma | Recruiting |
| NCT07405164 | Extension Study for Participants in Studies That Include Belzutifan… | Von Hippel-Lindau Disease | Recruiting |
| NCT07489495 | A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell… | Carcinoma, Renal Cell | Recruiting |
| NCT04586231 | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for… | Carcinoma, Renal Cell | Active, Not Recruiting |
| NCT04736706 | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and… | Carcinoma, Renal Cell | Active, Not Recruiting |
| NCT04195750 | A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal… | Carcinoma, Renal Cell | Active, Not Recruiting |
| NCT05239728 | A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus… | Carcinoma, Renal Cell | Active, Not Recruiting |
| Phase 2 | |||
| NCT07187778 | Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as… | Clear Cell Renal Cell Carcinoma | Recruiting |
| NCT06428396 | Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer… | Metastatic Breast Cancer | Recruiting |
| NCT07023432 | Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear… | Active Surveillance | Recruiting |
| NCT04924075 | Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL)… | Pheochromocytoma/Paraganglioma | Recruiting |
| NCT03401788 | A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau… | VHL - Von Hippel-Lindau Syndrome | Active, Not Recruiting |
| NCT07593040 | Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma | Renal Cell Carcinoma | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT02861573 | Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant… | Metastatic Castration-Resistant Prostate Cancer | Recruiting |
| NCT07049926 | Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma… | Renal Cell Carcinoma | Recruiting |
| NCT05468697 | A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan… | Renal Cell Carcinoma | Active, Not Recruiting |
| NCT04626518 | Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With… | Carcinoma, Renal Cell | Active, Not Recruiting |
| NCT04626479 | Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With… | Carcinoma, Renal Cell | Active, Not Recruiting |
| Phase 1 | |||
| NCT06234605 | A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell… | Renal Cell Carcinoma | Recruiting |